tbuckley/cabot-search huggingface dataset:
Is radiation therapy superior to conservative management in men with localized prostate cancer?
Authors: G. L. Lu-Yao, S. Kim, D. Moore, W. Shih, Y. Lin, R. S. DiPaola, A. L. Zietman, S. Yao
Journal: Journal of Clinical Oncology (2011)

73 Background: Radiation therapy is commonly employed for localized prostate cancer; however, there is little data regarding the comparative effectiveness of radiation therapy (RAD) vs. conservative management (CM). Methods: We performed a population-based cohort study, using Medicare claims data linked to the Surveillance, Epidemiology, and End Results data, to evaluate outcomes in 42,039 men aged 65-85 years treated with either primary RAD or CM for T1-T2 prostate cancer diagnosed in 1992-2005. To overcome potential biases associated with unmeasured confounding variables, we used instrumental variable analysis (IVA), a pseudo-randomization technique that captures the randomness associated with geographic variations in the use of RAD, to control for overt and hidden confounders. Results: The majority of patients (57%) had low-risk disease (Gleason score ≤7, PSA &lt;10, and T stage ≤T2a), and RAD was commonly used (60%) with considerable geographic variations. With median age 74 years and median follow-up 119 months, higher RAD use was not associated with improved survival in low-risk patients (10-year disease-specific survival differed by −0.9%, 94.9% vs. 95.8% in the highest and lowest tertile RAD use areas respectively; 95% C.I. −.1 to 0.6%). Among high-risk patients (Gleason score &gt;7 or PSA &gt;20), highest tertile RAD areas showed a borderline improved (2.7%) 10-year disease-survival (83.9% vs. 81.2% in the highest and lowest tertile radiation use areas; 95% C.I. −1.1% to 7.0%). The results in the moderate-risk group were between that of the low- and high-risk group. Primary RAD did not reduce future ADT use (odds ratios 0.95 for low-risk, 1.02 for moderate-risk, and 1.07 for high-risk with corresponding P values of 0.50, 0.86, and 0.51, respectively). Conclusions: In patients aged over 65 years old with low-risk prostate cancer, primary RAD is unlikely to improve 10-year disease-specific survival or prevent future ADT use. Weighing the potential risks and benefits of radiation therapy is critical for decision making. No significant financial relationships to disclose.
The NCI-60 Methylome and Its Integration into CellMiner
Authors: William C. Reinhold, Sudhir Varma, Margot Sunshine, Vinodh Rajapakse, Augustin Luna, Kurt W. Kohn, Holly Stevenson, Yonghong Wang, Holger Heyn, Vanesa Nogales, Sebastian Moran, David J. Goldstein, James H. Doroshow, Paul S. Meltzer, Manel Esteller, Yves Pommier
Journal: Cancer Research (2016)

A unique resource for systems pharmacology and genomic studies is the NCI-60 cancer cell line panel, which provides data for the largest publicly available library of compounds with cytotoxic activity (∼21,000 compounds), including 108 FDA-approved and 70 clinical trial drugs as well as genomic data, including whole-exome sequencing, gene and miRNA transcripts, DNA copy number, and protein levels. Here, we provide the first readily usable genome-wide DNA methylation database for the NCI-60, including 485,577 probes from the Infinium HumanMethylation450k BeadChip array, which yielded DNA methylation signatures for 17,559 genes integrated into our open access CellMiner version 2.0 (https://discover.nci.nih.gov/cellminer). Among new insights, transcript versus DNA methylation correlations revealed the epithelial/mesenchymal gene functional category as being influenced most heavily by methylation. DNA methylation and copy number integration with transcript levels yielded an assessment of their relative influence for 15,798 genes, including tumor suppressor, mitochondrial, and mismatch repair genes. Four forms of molecular data were combined, providing rationale for microsatellite instability for 8 of the 9 cell lines in which it occurred. Individual cell line analyses showed global methylome patterns with overall methylation levels ranging from 17% to 84%. A six-gene model, including PARP1, EP300, KDM5C, SMARCB1, and UHRF1 matched this pattern. In addition, promoter methylation of two translationally relevant genes, Schlafen 11 (SLFN11) and methylguanine methyltransferase (MGMT), served as indicators of therapeutic resistance or susceptibility, respectively. Overall, our database provides a resource of pharmacologic data that can reinforce known therapeutic strategies and identify novel drugs and drug targets across multiple cancer types. Cancer Res; 77(3); 601-12. ©2016 AACR.
Three-dimensional visualization of stranded source migration following prostate brachytherapy.
Authors: S. E. Daniel, A. Aref, C. Rabbani, R. Taylor, T. Campbell, F. Shamsa, P. J. Chuba
Journal: Journal of Clinical Oncology (2011)

79 Background: The use of radioactive seeds embedded in absorbable vicryl suture material has emerged as one preferred method for prostate cancer brachytherapy. However, it is unclear how strand displacement affects post-implant dosimetry. Our objective was to use CT imaging and 3D reconstruction to determine strand displacement between day zero and day 30 and to assess the dosimetric consequences of strand displacement. Methods: Between March 2006 and December 2009 there were 86 prostate brachytherapy patients with day zero and day 30 post-plan imaging. There was a mean of 18.24 strands per implant, 9.81 loose seeds per implant, and 69.08 total seeds per implant. Substantial strand displacement was identified by inspection. Migrated strands were identified on day zero and day 30 scans and the distance of displacement was measured using 3D fusion software. Results: Of 1550 strands placed, 23 were found to show substantial migration revealed by 3D imaging. These displacements occurred in 21 of the 86 cases. The estimated distance of strand displacement ranged from 0.5 cm to 2.5 cm with an average movement of 1.5 cm. The exact distance of strand displacement ranged from 0.31 m to 3.44 cm, with mean movement of 2.75 cm. Conclusions: 3D imaging reveals unexpected spatial instability in stranded brachytherapy sources. Significant movement may be expected to occur in approximately 1.48% of stranded sources and 24.42% of cases. Factors which predict for the migration of sources remain relatively undefined. Minimal dosimetric effects from strand displacement appear to be offset by resolution of prostate edema. [Table: see text] No significant financial relationships to disclose.
Efficacy of immediate post-TUR mitomycin-C (MMC) instillation in high-risk non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin (BCG).
Authors: J. Park, K. Song, M. Jo
Journal: Journal of Clinical Oncology (2011)

281 Background: To evaluate the efficacy of immediate post-TUR MMC instillation in high risk non-muscle-invasive bladder cancer treated with BCG. Methods: From January 2000 to December 2007, 162 high-risk non-muscle-invasive bladder cancer patients underwent TUR and BCG instillation at our institution. Among them 76 patients received additional immediate post-TUR MMC instillation (Group A), and remaining 86 patients underwent TUR and BCG instillation only (Group B). 60mg of MMC was mixed with 50ml of normal saline and was instilled in bladder within 2 hours after TUR. Tice strain BCG 12.5mg was used with 6-week induction course followed by 3-week maintenance every 3 months. The recurrence rate, time to recurrence, and stage and grade at recurrence were investigated. The mean follow-up was 33.4 months. Results: There were no significant differences in the characteristics of both groups, including age, sex, stage, and grade. Group A showed significantly lower recurrence rate than Group B (26.3% vs 48.8%, p=0.003). Group A showed somewhat longer time to recurrence but it was not statistically different (24.9 months vs 21.8 months, p=0.293). The change in stage and grade at recurrence were not different between 2 groups ( Table ). The 5-year recurrence free survival rate was significantly higher in Group A (72% vs 42%, p=0.003). Conclusions: The immediate post-TUR MMC instillation significantly reduced recurrence in high risk non-muscle-invasive bladder cancer patients treated by BCG. But it did not influenced the stage and grade at recurrence. [Table: see text] No significant financial relationships to disclose.
Subjective well-being and training load predict in-season injury and illness risk in female youth soccer players
Authors: Andrew Watson, Stacey Brickson, Alison Brooks, Warren Dunn
Journal: British Journal of Sports Medicine (2016)

<h3>Background</h3> The purpose of this study was to evaluate the effects of training load (TL) and well-being on injury and illness risk in youth soccer players. <h3>Methods</h3> Throughout a 20-week season, 75 female adolescent soccer players reported mood, fatigue, stress, soreness, sleep quality, sleep hours, TL, injuries and illnesses. Well-being measures were recorded from −3 (worst) to +3 (best). TL was expressed as daily, weekly and monthly, as well as an acute:chronic workload ratio (weekly divided by monthly). Variables were compared between days with and without an injury, and with or without an illness. Poisson regression models were developed to predict daily injuries and illnesses using well-being and TL (z-scores) as predictors. <h3>Results</h3> 36 injuries and 52 illnesses were recorded. Days with an injury had lower (worse) daily mood (1.24±0.2 vs 1.16±0.1, p=0.012) and higher daily TL (517±138 vs 440±158, p=0.010). Average monthly TL was higher preceding days with an illness (12 442 ±409 vs 12 627 ±403, p=0.043), while no differences were found with respect to other measures of TL or well-being. Worse daily mood (p=0.011, OR=0.012), higher daily TL (p&lt;0.001, OR=1.98), and higher prior day TL (p=0.040, OR=1.34) were independent predictors of injury, while weekly (p=0.005, OR=1.50) and monthly TL (p=0.007, OR=1.54) were predictors of illness. <h3>Conclusions</h3> Lower mood and higher acute TL are associated with increased injury risk, while higher chronic TL increases the risk of illness. Monitoring well-being and TL may facilitate intervention to reduce in-season injury and illness.
Factors associated with surgical resection for pancreatic and periampullary carcinomas in a cancer center in Mexico City.
Authors: Luis F. Onate-Ocana, Elyzabeth Bermudez-Benitez, Miguel Angel Ortiz-Toledo, Francisco J. Ochoa-Carrillo, Vincenzo Aiello-Crocifoglio
Journal: Journal of Clinical Oncology (2012)

191 Background: Medical information regarding periampullary neoplasms is scarce in Mexico. Therefore, our aim is to report our experience with pancreatic and periampullary neoplasms, with attention to factors associated to surgical resection in a Cancer Center. Methods: A retrospective analysis of medical records of all patients with malignant neoplasms located at periampullary region demonstrated by biopsy from January 2005 to December 2010. Factors associated to resectability or survival were calculated employing logistic regression or Cox models. Results: A total of 464 patients with neoplasms of the periampullary region were identified, 249 women and 215 males (mean age 60.2 years). Pancreatic cancer was reported in 269 cases (58%), ampullary in 91 (19.6%), duodenal in 63 (13.6%), intrapancreatic bile duct in 15 (3.2%), neuroendocrine neoplasms in 13 (2.8%) and other types in 13 (2.8%). Sixty-two pancreatoduodenectomies were performed in this 6-year period (13.4% resectability). Sixty-one patients were stages I or II, and 403 stages III or IV. Age (odds ratio [OR] 0.97; 95% confidence interval [CI] 0.96-0.99) and ampullary carcinoma (OR 6.09; 95% CI 3.4-10.8) were the only factors associated to resectability (p&lt;0.0001). Median overall survival of the cohort was 2.9 months (95% CI 2.4-3.4). Factors associated to overall survival with their estimators of the Cox model (p&lt;0.00001) are shown in the Table. Conclusions: Resectability is low and advanced stages are frequent. Young age and location in the ampulla defines increased probability of resection. Overall survival is associated to younger age, being female, ampullary carcinoma, neuroendocrine carcinoma and surgical resection. [Table: see text]
Treatment patterns of breast cancer patients in Georgia Medicaid: Are patterns different for BCCPTA women?
Authors: E. K. Adams, S. G. A. Gabram, L. Chien
Journal: Journal of Clinical Oncology (2011)

153 Background: The Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) of 2000 allowed states to cover women diagnosed with breast, cervical, or pre-cancerous cervical conditions under Medicaid upon diagnosis and while “under treatment”. We investigate breast cancer treatment of patients enrolled under BCCPTA in Georgia. Methods: Georgia Comprehensive Cancer Registry were linked to Medicaid enrollment files to identify 2,048 enrollees with a primary cancer of breast, of whom 1,046 were BCCPTA, 674 were disabled, and 328 were in ‘other’ Medicaid eligibility groups. Logistic regressions were used to estimate the odds of receiving: (1) lumpectomy, (2) mastectomy, and (3) other surgery in addition to (4) any drug regimen (hormonal or chemotherapy) and (5) radiation. Results: Using descriptive data and after controlling for covariates, BCCPTA women are more likely to receive any treatment (OR = 4.71, [CI] = 2.48, 8.96), any drug regimen (OR = 3.58, [CI] =2.32, 5.51), any radiation (OR = 1.61, [CI] = 1.15, 2.24), and any ‘definitive’ surgery (OR = 2.52, [CI] = 1.74, 3.66) than the ‘other’ eligibility group. There are no significant differences in the receipt of a lumpectomy versus a mastectomy by eligibility group but BCCPTA women are more likely to receive more adjuvant follow-up. Conclusions: The BCCPTA program in Georgia appears to create a quicker pathway for previously low-income uninsured women with breast cancer to access services and in turn, receive more treatment than women enrolled in more traditional, Medicaid eligibility groups. Yet, the overall rate of adjuvant therapy, whether radiation or hormonal/chemotherapy, appears to fall short of national criteria. [Table: see text]
Response by Li et al to Letter Regarding Article, “Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria Due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart”
Authors: Ning Li, Brian J. Hansen, Vadim V. Fedorov
Journal: Circulation (2016)
Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
Authors: G. Sonpavde, G. R. Pond, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, A. J. Armstrong
Journal: Journal of Clinical Oncology (2011)

118 Background: In men with metastatic castration resistant prostate cancer (CRPC),the association of measurable tumor responses with overall survival (OS) is unknown. We retrospectively evaluated the TAX327 phase III trial to study this relationship. Methods: Eligible patients for this analysis included those with WHO-defined measurable metastatic disease randomized to receive either docetaxel or mitoxantrone. OS was estimated using the Kaplan-Meier method and the prognostic relationship of WHO-defined radiologic response with OS was performed using Cox proportional hazards regression. Landmark analyses evaluated survival from baseline and 2, 3, 4 and 6 months after baseline. Results: Four hundred and twelve patients enrolled on the TAX327 trial had measurable tumors. Thirty-seven patients exhibited a complete or partial objective response (CR/PR, 9.0%), 116 had stable disease (SD, 28.2%), 99 had progressive disease (PD,24%) and 160 (38.8%) did not have a post-baseline objective assessment. Partial responders demonstrated longer median OS (29.0 months) than patients with SD (22.1 months), or those with PD (10.8 months) or those who were not assessed (12.7 months). These results remained after landmark analysis. We found a significant association between ≥30% PSA declines and radiologic response, with ≥30% PSA declines occurring in all patients with CR/PR, 79.8% of patients with SD and 34.4% with PD. Radiologic response remained a significant but modest post-treatment prognostic factor for OS after adjusting for treatment, pain-response and ≥30% PSA-decline (p=0.009). Conclusions: In men with metastatic CRPC and measurable disease receiving chemotherapy, objective tumor response was prognostic for OS, and appears to complement PSA assessment. [Table: see text]
Newborn Screening for Sickle Cell Disease in Brussels, a Program with an Ongoing Clinical Outcome Improvement
Authors: Phu-Quoc Le, Beatrice Gulbis, Laurence Dedeken, Anna Vanderfaeillie, Catherine Heijmans, Christiane Vermylen, Sophie Huybrechts, Christine Devalck, Frederic Cotton, Ba Cuong Nguyen, Françoise Vertongen, Malou Ngalula, Alina Ferster
Journal: Blood (2012)
Aberrant Expression of the Chondroitin Sulfate Proteoglycan NG2 on Pediatric AML/abn(11q23) and ALL/t(4;11) Does Not Allow Flow Cytometric Detection of Leukemic Blasts with a Stem Cell-Like Immunophenotype.
Authors: Janna Neudenberger, Marc Hotfilder, Annegret Rosemann, Claudia Langebrake, Dirk Reinhardt, Josef Vormoor
Journal: Blood (2004)
Non-Invasive Assessment of Pancreatic Iron Stores by Magnetic Resonance Imaging (MRI) in β-Thalassemic Patients.
Authors: Reijane Alves De Assis, Andreza Alice Feitosa Ribeiro, Alexandre Henrique C Parma, Laércio Alberto Rosemberg, Cesar Higa Nomura, Fernando Uliana Kay, Sandra Regina Loggetto, Aderson S Araujo, Antonio Fabron, Mônica Pinheiro de Almeida Veríssimo, Giorgio Roberto Baldanzi, Fabricio Biscaro Pereira, Merula A. Steagal, Claudia Angela Galleni di Sessa Velloso, Bruno Sposito, Sandra Saemi Nakashima, Michelli da Silva Diniz, Ronaldo Hueb Barone, John C Wood, Nelson Hamerschlak
Journal: Blood (2009)
Pancreatic neuroendocrine tumors: Twenty years’ experience of 100 patients at a single center.
Authors: Satoshi Shiba, Chigusa Morizane, Shunsuke Kondo, Hideki Ueno, Masafumi Ikeda, Tomohiro Yamaguchi, Takuji Okusaka, Kazuaki Shimada, Tomoo Kosuge, Nobuyoshi Hiraoka
Journal: Journal of Clinical Oncology (2012)

179 Background: Pancreatic neuroendocrine tumors (NETs) are rare neoplasms that exhibit a variety of diverse morphological, functional and behavioral characteristics. However, only a few reports have evaluated large case series of pancreatic endocrine tumors. Methods: We conducted a retrospective review of 100 consecutive patients with pancreatic NETs diagnosed pathologically and treated at the National Cancer Center Hospital between 1991 and 2010. Results: The characteristics of the 100 patients were as follows: male, 49; female, 51; median age, 55 years. Fourteen patients gave a history of endocrine symptoms at the time of diagnosis. The primary tumors arose in the head, body and tail of the pancreas in 54, 25 and 21 patients, respectively. According to the 2010 grading classification of the World Health Organization, 11 patients were classified as having NET G1, 44 as having NET G2 and 29 as having NEC. The five-year survival rates of the patients with NET G1, NET G2 and NEC were 91%, 78% and 12%, respectively. The five-year survival rates of the patients with stage I, II and III, and IV disease classified according to the American Joint Committee on Cancer (AJCC) were 100%, 68% and 9%, respectively. Distant metastases occurred in 18% percent of the NET G1 patients, 39% of the NET G2 patients and 83% of the NEC patients. Treatment was undertaken by surgical resection in 82%, 59% and 24% of patients with NET G1, NET G2 and NEC, respectively. The five-year survival rates of the patients with NET G1, NET G2 and NEC after radical surgery were 100%, 91% and 36%, respectively. Among the 33 patients treated by systemic chemotherapy, the median survival period was 22.9 months in the patients with NET G1/G2 and 6.6 months in those with NEC. A multivariate analysis identified lower age, good performance status (PS) and lower histopathologic grade as independent favorable prognostic factors. Conclusions: Patients with NET G1, G2 treated by surgical resection had a good prognosis. Most patients with NEC exhibited distant metastases and had a poor prognosis. Histopathologic grade is an important factor for selecting the appropriate treatment strategy and predicting the prognosis in patients with pancreatic NETs.
Triple-negative breast cancer (TNBC) outcomes with partial breast irradiation and concurrent chemotherapy (PBI-CC) compared with whole breast irradiation and sequential chemotherapy (WBI-SC).
Authors: L. M. De Souza Lawrence, A. Shah, V. Stearns, F. Asrari, D. A. Frassica, T. N. Tsangaris, J. H. Fetting, J. R. Lange, L. K. Jacobs, R. C. Zellars
Journal: Journal of Clinical Oncology (2011)

115 Background: TNBC (ER/PR/HER2-negative) is associated with worse locoregional recurrence (LRR), disease-free survival (DFS), and overall survival (OS) than non-TNBC. MSKCC/Harvard recently reported a 5-yr local recurrence rate of 33% in TNBC patients treated with PBI (Pashtan et. al. ASTRO 2010). Having completed two prospective trials of PBI-CC, one previously reported (Zellars et al. JCO 2009), we reviewed the outcomes of TNBC patients treated with PBI-CC and compared them to those treated with WBI-SC. Methods: TNBC patients treated on 2 phase I/II PBI-CC protocols were compared to a cohort of TNBC patients treated at our institution with WBI-SC with respect to OS, DFS, LRR and in-breast tumor recurrence (IBTR). KM rates of local and distant recurrence, log-rank test of statistical significance are presented. Results: Between 2004 and 2009, 16 patients were treated with PBI-CC and 32 with WBI-SC. PBI-CC was 40.5 Gy (2.7 Gy x 15 QD) to the lumpectomy bed only with cycle 1 of ddAC (60/600 mg/m 2 every 14 days with growth factor support x 4 cycles). WBI-SC patients received a med. dose (+ boost) of 60.7 Gy, (42.5 – 66), 5/32 had nodal irradiation. 28/32 recieved AC, and 4/32 C, Docetaxel. Med. follow-up is 38.4 mo (9.2–65.5) and 40.5 mo (5.6–77.8), respectively. There is no statistically significant difference between groups with respect to T/N stage, median age, and menopausal status. No patients died. All 6 recurrences (1 nodal, 4 IBTR, 1 distant) were in the WBI-SC group. Med. time to recurrence was 14.4 months (0.8–38.6). DFS at 3 yr/5 yr were 100% vs. 84.4% (p=0.10) and 100% vs. 81.3%. (p=0.07) in the PBI-CC and WBI-SC groups respectively. There is a trend towards decreased LRR (0% vs. 15.6%, p=0.12) and IBTR (0% vs. 12.5% , p=0.16), in favor of PBI-CC. Conclusions: Our results differ from earlier reports of a high rate of LRR in TNBC patients treated with PBI. This may be due to our use of concurrent chemotherapy with PBI or to undefined factors in our series of WBI-SC. Our data suggest improved DFS, LRR, and IBTR with PBI-CC when compared to retrospectively reviewed contemporary TNBC patients treated WBI-SC and should be externally confirmed.
Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation.
Authors: Chiara Gentilini, Anne Letsch, Annemarie Asemissen, Arne Muessig, Katrin Rieger, Carmen Scheibenbogen, Eckhard Thiel, Lutz Uharek
Journal: Blood (2006)